Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard ...

Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and ...

BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Pharmaceutical giant Bristol Myers Squibb is currently offering a 4.7% yield. The dividend hasn't been increased every single ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma, by Bristol ...

This initiative marks among the BMS Foundation’s first grants in India to increase access to screening and build capacity to ...

Cobenfy’s efficacy at treating the symptoms of patients with psychosis may vary between subgroups, according to a post-hoc ...